

	Product	Anthor to mand back	to all scalles
		Active Ingredient	Indication
SI. No.	Cardiology		
1	STATIX®	Atorvastatin 10/20/40/80 mg tablets	Controls elevated cholesterol levels
2	STATIX® F	Atorvastatin 10 mg + Micronised Fenofibrate 200 mg tablets	For Diabetic Dyslipidemia
3	STATIX® - EZ	Atorvastatin 10 mg + Ezetimibe 10 mg tablets	Controls extremely high levels of cholesterol
4	TELMISAT®	Telmisartan 20/40/80 mg tablets	Offers 24 hour blood pressure control
5	TELMISAT®-H	Telmisartan 40/80 mg + Hydrochlorothiazide 12.5 mg tablets	In uncontrolled Hypertension
6	TELMISAT® AM	Telmisartan 40 mg + Amlodipine 5 mg tablets	In Diabetic Hypertensives
7	ACTIBLOK - IPR	Metoprolol Immediate & Patterned Release 25/50/100 mg tablets	In patients of Hypertension, Angina, IHD and Heart Failure
8	ACTIBLOK AM®	Metoprolol Succinate IPR 25/50 mg +Amlodipine 5 mg tablets	In Uncontrolled Hypertension
9	BESTOR®	Rosuvastatin 5/10/20 mg tablets	For the management of Dyslipidemia and Atherosclerosis
10	BESTOR® FN	Rosuvastatin 10mg + Nanonized Fenofibrate 145 mg	In diabetes patients with combined hyperlipidmia
11	ZARGO*	Losartan Potassium 25/50 mg tablets	In hypertensive patients with CV co-morbidity
12	ZARGO* - H	Losartan Potassium 50 mg + Hydrochlorothiazide 12.5 mg tablets	In severe Hypertensive patients
13	MYOKINASE®	Recombinant Streptokinase for injection 1,500,000 IU	In patients of Acute Myocardial Infarction
14	DYNALIX®	Enoxaparin 40/60 mg Pre Filled Syringe	In patients of Acute Coronary Syndrome and Prophylaxis of Deep Vein Thrombosis
15	CLOTIDE*	Eptifibatide 10 ml bolus/100 ml for infusion	In ACS patients, undergoing Percutaneous Coronary Interventions
16	TIROZEST™	Tirozest HCL 5 mg/100 ml vial	In high risk ACS patients with NSTEMI

SI. No.	Diabetology		
			INSUPen® is to be used only with Biocon's Insugen-R Refil™,
			Insugen-N Refil™,
		INSUPen is a reusable insulin pen that can deliver insulin doses	Insugen-30/70 Refil™,
1	INSUPen®	from 1 unit (0.01mL) to 60 units (0.60 mL) in increments of 1 unit.	Insugen 50/50 Refil™ and
			BASALOG Refil™,
2			refilled 3mL insulin cartridges
2	Insugen-30/70 Refil™	Each ml contains Human Insulin (rDNA origin), 100 IU.	To reduce blood glucose levels in all types of diabetes.
3	Insugen-50/50 Refil™	Each ml contains Human Insulin (rDNA origin), 100 IU.	To reduce blood glucose levels in all types of diabetes.
4	Insugen-N Refil™	Each ml contains Human Insulin (rDNA origin), 100 IU.	To reduce blood glucose levels in all types of diabetes.
5	Insugen-R Refil™	Each ml contains Human Insulin (rDNA origin), 100 IU.	To reduce blood glucose levels in all types of diabetes.
6	BASALOG Refil™	Each ml contains Insulin Glargine (rDNA Origin), 100 IU.	To provide 24 hours basal insulin action in all types of diabetes
7	INSUGEN® 30/70 40 IU	Each ml contains Human Insulin (rDNA origin), IP 40 IU	To reduce blood glucose levels in all types of diabetes
8	INSUGEN® 50/50 40 IU	Each ml contains Human Insulin (rDNA origin), IP 40 IU	To reduce blood glucose levels in all types of diabetes
9	INSUGEN® N 40 IU	Each ml contains Human Insulin (rDNA origin), IP 40 IU	To reduce blood glucose levels in all types of diabetes
10	INSUGEN® R 40 IU	Each ml contains Human Insulin (rDNA origin), IP 40 IU	To reduce blood glucose levels in all types of diabetes
11	Insugen® 30/70 100 IU	Each ml contains Human Insulin (rDNA origin), IP 100 IU	To reduce blood glucose levels in all types of diabetes
12	Insugen® 50/50 100 IU	Each ml contains Human Insulin (rDNA origin), IP 100 IU	To reduce blood glucose levels in all types of diabetes
13	Insugen® N 100 IU	Each ml contains Human Insulin (rDNA origin), IP 100 IU	To reduce blood glucose levels in all types of diabetes
14	Insugen® R 100 IU	Each ml contains Human Insulin (rDNA origin), IP 100 IU	To reduce blood glucose levels in all types of diabetes
15	BASALOG®	Each ml contains Insulin Glargine (rDNA Origin) 100 IU	To provide 24 hours basal insulin action in all types of diabetes
16	BLISTO®	Glimepiride 1/2/4 mg	For monotherapy or combination therapy of type 2 diabetes
17	BLISTO MF®	Glimepiride 1 mg + Metformin 500 mg SR & Glimepiride 2/4 mg + Metformin	For type 2 diabetes inadequately controlled with a single drug
17		1000 mg SR	
18	METADOZE-IPR*	Metformin 500/850 mg IPR	For monotherapy or combination therapy of type 2 diabetes
19	TriGPM*	Glimepiride 1/2 mg + Pioglitazone 15 mg + Metformin 500 mg ER	For type 2 diabetes inadequately controlled with a combination therapy of 2 drugs
20	ZUKER®-MF	Gliclazide 80 mg + Metformin 500 mg SR	For type 2 diabetes inadequately controlled with a single drug
21	PIODART®	Pioglitazone 15/30 mg	For monotherapy or combination therapy of type 2 diabetes
22	PIODART®-MF	Pioglitazone 15 mg + Metformin ER 500 mg	For type 2 diabetes inadequately controlled with a single drug
23	OLISAT®	Orlistat 60/120 mg	For weight reduction in overweight or obese people
24	GABIL®	Gabapentin 300 mg + Methylcobalamin 500 mcg	To reduce symptoms of diabetic neuropathy
25	GMAB® Plus	GLA 100 mg + Methylcobalamin 1500 mcg + ALA 100 mg +	Nutritional supplementation in patients with diabetes
		Benfothiamine 100 mg + Elemental Zinc 15 mg	
26	VOLICOSE*	Voglibose 0.2/0.3 mg	To reduce post-prandial plasma glucose levels in patients with diabetes
27	METADOSE® V	Voglibose 0.2/0.3 mg+ Metformin 500 mg For type 2 diabetes	For type 2 diabetes inadequately controlled with a single drug

Sl. No.	Nephrology		
1	ERYPRO safe™	Recombinant Human Erythropoietin Alpha injection in strengths of 2000/3000/4000/5000/6000/10000 IU	For the treatment of patients with anemia due to chronic renal failure, either on dialysis or not on dialysis
2	ERYPRO™ - Vial	Recombinant Human Erythropoietin Alpha 2000/4000/10000 IU	For the treatment of patients with anemia due to chronic renal failure, either on dialysis or not on dialysis
3	ERYPRO™ – PREFIL	Recombinant Human Erythropoietin Alpha 2000/4000 IU	For the treatment of patients with anemia due to chronic renal failure, either on dialysis or not on dialysis
4	TACROGRAF™	Tacrolimus .25/0.5/1/2 mg capsules	Prophylaxis of organ rejection in patients receiving allogenic liver, kidney or heart transplantation
5	RENODAPT®	Mycophenolate Mofetil 250 mg capsules and 500/750 mg tablets	Prophylaxis of organ rejection in patients receiving allogenic renal, heart or liver transplantation
6	RENODAPT®-S	Mycophenolic Acid 180/360 mg tablets	Prophylaxis of organ rejection in patients receiving allogenic renal transplantation
7	CYCLOPHIL ME® (ORAL SOLUTION)	Cyclosporine Oral Solution USP 100 mg/ml	Prophylaxis of organ rejection in kidney, liver and heart allogenic transplantation
8	CYCLOPHIL ME®	Cyclosporine USP 25/50/100 mg capsules	Prophylaxis of organ rejection in kidney, liver and heart allogenic transplantation
9	RAPACAN™	Sirolimus 1mg tablets	Prophylaxis of organ rejection in patients aged 13yrs or older receiving renal transplantation
10	Advacan™	Everolimus 0.25/0.5 mg tablets	Prophylaxis of organ rejection in adult patients at low to moderate immunologic risk receiving a kidney or cardiac transplantation
11	Narita™+	Whey protein supplement fortified with vitamins and minerals, 200 gm tin	Nutritional supplement in patients of chronic renal failure, including patients on dialysis
12	biOSEV™	Sevelamer HCl 400/800 mg tablets	Control of serum phosphorous in patients with chronic kidney disease on dialysis
13	NEPORIN™	Heparin Sodium 5000/25000 IU	For adequate anticoagulation in haemodialysis

SANTIB**  Capecitabine IP 150/500mg  Capecitabin	ci Na I	On and house a subine		
A Parametr			Nimotuzumah 200 mg humanized monoclonal antihody	For the treatment of locally advanced squamous cell carcinoma of head and neck
2   Aircanava*   Positional or procession consideration from injectable assertion (all lumino bound)   for the treatment of metastack breast camer	1 1	BIOMAb EGFR®		
4 NULL safe**   Figurestern Recombinant Humann Granulocyce Colony Stimulating Facility 300; pt.   5 NULL Safe**   Figurestern Recombinant Humann Granulocyce Colony Stimulating Facility 300; pt.   6 NULL Safe**   Figurestern Recombinant Humann Granulocyce Colony Stimulating Facility 300; pt.   7 Option**   Conceiling Safe Safe Safe Safe Safe Safe Safe Safe	2 /	Abraxane®		
5 NURLY Programming commissioned trained confidence for the restriction of software of the restriction of software for the restriction of the restriction of software for the restriction of the primary tumor + for the restriction of software for software for software for the restriction of the primary tumor + for the restriction of the primary tumor + for software for software for software for the restriction of the primary tumor + for software for				
Section				
Poercome   Construct   Const				
Section				
Controlled Caretre   As a single agent of adjustant treatment in patients with coderectal cancer who have undergone complete resection of the primary fumor * for relatable*   Pack Caretre				
* As a single agent for adjacent treatment in patients with concretal and cancer who have undergore complete resoction of the primary furnor * institutation.*  **Breat Cancer**  **In contriction with Disordard for the treatment of patients with locally advanced grant of the primary furnor * institutation.*  **Breat Cancer**  **In contriction with Disordard for the treatment of patients with locally advanced grant of the patients with primary furnor * in contribution with pacification with paci	0 1	Evertor	renal cell carcinoma	
**In combination with packtased as first-line retement of patients with cancer, after failure of prior authorscycline containing adjavant chemothe anthracyclines were clinically contraindicated.  **Non-Small Cell Lung Cancer**  **In Combination with Cisplatin for the first-line treatment of patients with incorporate locally advanced (Stage III A or IIII) or metast XSCLC.  **Paccasic Cancer**  **Paccasic C	9 )	XORTIB™	Capecitabine IP 150/500mg	<ul> <li>As a single agent for adjuvant treatment in patients with colorectal cancer Dukes' C Colon cancer who have undergone complete resection of the primary tumor • For the treatment of metastatic</li> <li>Breast Cancer</li> <li>In combination with Docetaxel for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy</li> <li>Gastric Cancer</li> <li>For first-line treatment of advanced gastric cancer in combination with a platinum-based</li> </ul>
• In combination with Cisplatin for the initial treatment of patients with the metastatic nonsquamous NSCLC. For the maintenance treatment of patients with cally advanced or metastatic nonsquamous NSCLC whose disease has not prog cycles of platinum-based first-line chemotherapy. As a single-agent for the patients with locally advanced or metastatic nonsquamous NSCLC after patients with locally advanced or metastatic nonsquamous NSCLC after patients with more patients with with patients with decay patients with the patients with with patients. Patients with patients with with patients with patients with with patients with patients. Patients with patients with patients with patients with patients with patients. Patients with patients with patients with patients with patients with patients with patients. Patients with patients	10 /	ATSURE®	Gemcitabine Hydrochloride - 200 mg/1 gm./ 1.4 gm.	In combination with paclitaxel as first-line treatment of patients with metastatic breast cancer, after failure of prior anthracycline containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.  Non-Small Cell Lung Cancer In combination with Cisplatin for the first-line treatment of patients with inoperable locally advanced (Stage III A or IIIB) or metastatic (Stage IV) NSCLC.  Pancreatic Cancer First-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Also indicated for patients previously treated with 5-FU.
Lenalidomide − 5/10/25 mg	11 5	SYMYX™	Pemetrexed 100/500 mg	In combination with Cisplatin for the initial treatment of patients with locally advanced or metastatic nonsquamous NSCLC. For the maintenance treatment of patients with locally advanced or metastatic nonsquamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. As a single-agent for the treatment of patients with locally advanced or metastatic nonsquamous NSCLC after prior chemotherapy.  Mesothelioma In combination with Cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for
13 ADNEXA®   Epirubicin Hydrochloride BP 10/50 mg   involvement following resection of primary breast cancer.     14 XTIDE®   Oxaliplatin USP 50/100 mg   For the treatment of advanced colorectal cancer     15 TAZENTA™   Bortezomib 2mg   For the treatment of patients with multiple myeloma In mantle cell lymph received at least 1 prior therapy	12 H	HUMIX®	Lenalidomide – 5/10/25 mg	In combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy  Myelodysplastic Syndromes For the treatment of patients with transfusion-dependent anaemia due to low or intermediate 1-risk Myelodysplastic syndromes associated with a deletion 5q cytogenetic
TAZENTA™  Bortezomib 2mg  For the treatment of patients with multiple myeloma In mantle cell lymph received at least 1 prior therapy  Chronic Lymphocytic Leukaemia (CLL) For the treatment of patients with Non-Hodgkin's Lymphoma For the treatment of patients with indolent B-lymphoma that has progressed during or within six months of treatment rituximab containing regimen  SI. No. Immunotherapy  Each vial contains 25 mg of itolizumab.  1 ALZUMAb™ Itolizumab is a humanized recombinant anti-CD-6 monoclonal antibody.  Each mL contains 5 mg of itolizumab for intravenous use.  2 PICON® Pimecrolimus cream 1% w/w  3 TBIS® Tacrolimus ointment 0.03%/0.1% w/w  Mild to Moderate a Severe Dematitis  4 CALPSOR™ Calcipotriol ointment 0.005%w/w  Mild to Moderate Plaque Psoriasis	13	ADNEXA®	Epirubicin Hydrochloride BP 10/50 mg	As a component of adjuvant therapy in patients with evidence of axillary node tumour involvement following resection of primary breast cancer.
TAZENTA™  Bendamustine Hydrochloride 100 mg  Bendamustine Hydrochloride 100 mg  SI. No. Immunotherapy  SI. No. Immunotherapy  Each vial contains 25 mg of itolizumab. Itolizumab is a humanized recombinant anti-CD-6 monoclonal antibody. Each mL contains 5 mg of itolizumab for intravenous use.  PICON® Pimecrolimus cream 1% w/w  Tascolimus ointment 0.03%/0.1% w/w  Biss® Tascolimus ointment 0.03%/0.1% w/w  CALPSOR™ Calcipotriol ointment 0.005%w/w  Mild to Moderate Deque Psoriasis  Mron-Hodgkin's Lymphoma For the treatment of patients with indolent B-lymphoma that has progressed during or within six months of treatment rituximab containing regimen  A novel biologic for the treatment of moderate-to-severe psoriasis.  A novel biologic for the treatment of moderate-to-severe psoriasis.  ALZUMAb™ is indicated for the treatment of patients with active modera plaque psoriasis who are candidates for systemic therapy.  Mild to Moderate atopic Dermatitis  Tascolimus ointment 0.03%/0.1% w/w  Mild to Moderate Plaque Psoriasis	14	XTIDE*	Oxaliplatin USP 50/100 mg	
Chronic Lymphocytic Leukaemia (CLL) For the treatment of patients with Non-Hodgkin's Lymphoma For the treatment of patients with indolent B-lymphoma that has progressed during or within six months of treatment rituximab containing regimen    SI. No.   Immunotherapy	15	TAZENTA™	Bortezomib 2mg	For the treatment of patients with multiple myeloma In mantle cell lymphoma who have
Each vial contains 25 mg of itolizumab.  1 ALZUMAb™ Itolizumab is a humanized recombinant anti-CD-6 monoclonal antibody. Each mL contains 5 mg of itolizumab for intravenous use.  2 PICON® Pimecrolimus cream 1% w/w Mild to Moderate atopic Dermatitis  3 TBLS® Tacrolimus ointment 0.03%/0.1% w/w Moderate to Severe Dermatitis  4 CALPSOR™ Calcipotriol ointment 0.005%w/w Mild to Moderate Plaque Psoriasis	16	XNTA™	Bendamustine Hydrochloride 100 mg	Chronic Lymphocytic Leukaemia (CLL) For the treatment of patients with CLL Non-Hodgkin's Lymphoma For the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a
Each vial contains 25 mg of itolizumab.  A LZUMAb™ Itolizumab is a humanized recombinant anti-CD-6 monoclonal antibody. Each mL contains 5 mg of itolizumab for intravenous use.  PICON® Pimecrolimus cream 1% w/w Mild to Moderate atopic Dermatitis  Tacrolimus ointment 0.03%/0.1% w/w Moderate to Severe Dermatitis  CALPSOR™ Calcipotriol ointment 0.005%w/w Mild to Moderate Plaque Psoriasis	SI No I	Immunotherany		
ALZUMAb™ Itolizumab is a humanized recombinant anti-CD-6 monoclonal antibody.  Each mL contains 5 mg of itolizumab for intravenous use.  PICON® Pimecrolimus cream 1% w/w Mild to Moderate atopic Dermatitis  TBLS® Tacrolimus ointment 0.03%/0.1% w/w Moderate to Severe Dermatitis  CALPSOR™ Calcipotriol ointment 0.005%w/w Mild to Moderate Plaque Psoriasis	oi. IVO. I		Fach vial contains 25 mg of itolizumah	A novel highgir for the treatment of moderate-to-severe psoriasis
2     PICON®     Pimecrolimus cream 1% w/w     Mild to Moderate atopic Dermatitis       3     TBIS®     Tacrolimus ointment 0.03%/0.1% w/w     Moderate to Severe Dermatitis       4     CALPSOR™     Calcipotriol ointment 0.005%w/w     Mild to Moderate Plaque Psoriasis	1		Itolizumab is a humanized recombinant anti-CD-6 monoclonal antibody.	ALZUMAb™ is indicated for the treatment of patients with active moderate to severe chronic
4 CALPSOR™ Calcipotriol ointment 0.005%w/w Mild to Moderate Plaque Psoriasis				
5   CALPSUK:"C   Calcipotriol ointment 0.005%w/w + Clobetasol Propionate 0.05% w/w   Moderate to Severe Plaque Psoriasis				
6 PSORID™ Cyclosporin capsules 25/50/100 mg Cyclosporin oral solution 100 mg/ml Severe Psoriasis	ь	roUKID	Cyclosporin capsules 25/50/100 mg Cyclosporin oral solution 100 mg/ml	Severe Psoriasis

SI. No.	Comprehensive Care		
31. IVO.	Comprehensive care		Pneumonia
			Febrile Neutropenia
1	CELRIM®	Cefepime 1g	Urinary Tract Infections
			Uncomplicated Skin and Skin Structure Infections
			Complicated Intra-abdominal Infections
			Urinary tract infections
2	CELRIM TZ®	Cefepime 1g & Tazo bactam 0.125 g	Skin and skin structure infections and
			Complicated intra-abdominal infections
			Intra-abdominal Infections
			Skin and skin structure infections
3	Biopiper TZ™	Piperacillin 4 g & Tazobactam 0.5 g	Postpartum endometritis or pelvic inflammatory disease
			· · · · · · · · · · · · · · · · · · ·
			Community-acquired pneumonia
			Intra- abdominal Infections
4	Biopiper TZ™ 2.25	Piperacillin 2g and tazobactam 250mg	Skin and skin structure infections
			Postpartum endometritis or pelvic inflammatory disease
			Community-acquired pneumonia
			Lower respiratory tract infections
			Urinary tract infections
			Intra-abdominal infections
_			Gyneacologic infections
5	IMICELUM™	Imipenem 500 mg & Cilastatin 500 mg	Bacterial septicemia
			Bone and joint infections
			Skin and skin structure infections
			Endocarditis
			Lower respiratory tract infections
_		- 4	Complicated upper and lower urinary tract infections
6	GENPIROME®	Cefpirome 1g	Bacteremia/Septicaemia
			Febrile neutropenia
			Skin and soft tissue infections
			Skin and Skin Structure Infections
7	PENMER® - 500	Meropenem 500 mg	Intra-abdominal Infections
			Bacterial Meningitis
			Skin and Skin Structure Infections
8	PENMER*	Meropenem 1g	Intra-abdominal Infections
Ŭ	PENIMER*	meropenen 18	Bacterial Meningitis
			In Gram-Positive infections:
			VRE infections
	ENTAVAR™	Lineardid LV 200 mg/200 ml	
	ENTAVAK	Linezolid I.V 200 mg/300 ml	Nosocomial pneumonia
			Skin and skin structure infections
			Diabetic foot infections
			In Gram-Positive infections:
			VRE infections
	ENTAVAR™ - 600	Linezolid Tablet 600 mg	Nosocomial pneumonia
			Skin and skin structure infections
			Diabetic foot infections
			Gram positive infections in the following:
	TECONIN™	Teicoplanin 200/400mg	• skin and soft tissue infections
			urinary tract infections
			lower respiratory tract infections
9			
			joint and bone infections
			septicaemia
			• endocarditis
			peritonitis
	VANCOWAR CP™	Vancomycin 500mg	MRSA infections in the following:
			Septicaemia
10			bone infections
10			lower respiratory tract infections
l			• skin lower respiratory tract infections
			Respiratory Tract Infections
			Urinary Tract Infections
11	CEGAVA™	Cefoperazone 1g and Sulbactam 500mg 2. Cefoperazone 500mg and Sulbactan	
			Intra-abdominal infections
			Skin and Soft Tissue Infections
			Bone and Joint Infections
1			Pelvic Inflammatory Disease

Respiratory Tract Infections			I	
12   CEGAVA TZ ™   Cefoperazone 1g and Tazobactam 125mg   Intra-abdominal infections   Intra-abdominal infections   Intra-abdominal infections   Skin and Sort Tissue Infections   Bone and Joint Infections   Lower respiratory tract infections   Community-acquired pneumonia   Acute bacterial otitis media   Skin and Sort structure infections   Unimary tract infections   Acute bacterial otitis media   Skin and skin structure infections   Acute bacterial otitis media   Skin and skin structure infections   Unimary tract infections				
Intra-abdominal infections				
Intra-abdominal infections	12	CEGAVA TZ ™	Cefoperazone 1g and Tazobactam 125mg	
Bone and Joint Infections  Lower respiratory tract infections  community-acquired pneumonia  Acute bacterial otitis media SUPRAVA TZ™  Ceftriaxone 1 g + Tazobactam 125mg  Ceftriaxone 1 g + Tazobactam 125mg  Ceftriaxone 1 g + Tazobactam 125mg  Lower respiratory tract infections Urinary tract infections Uncomplicated gonorrhoea  Lower respiratory tract infections Acute bacterial otitis media Skin and skin structure infections Acute bacterial otitis media Skin and skin structure infections Urinary tract infections Urinary tract infections Urinary tract infections Bone and joint infections Intra-abdominal infections Intra-abdominal infections Intra-abdominal infections Meningitis Sursical prophylaxis  Constipation  Acinetobacter induced: Nosocomial Pneumonia Bacteremia UTI Surgical Site wound infections Post neurological meningitis UTI Surgical Site wound infections Post neurological meningitis Uncorrections Post neurological meningitis Uncorrections	1	CEGAVA 12		
Lower respiratory tract infections				
Ceftriaxone 1 g + Tazobactam 125mg  Ceftriaxone 500mg / 1g  SUPRAVA™  Ceftriaxone 500mg / 1g  Ceftriaxone 500mg /				
SUPRAVA TZ™  Ceftriaxone 1 g + Tazobactam 125mg  • Acute bacterial otitis media • Skin and skin structure infections • Unirary tract infections • Uncomplicated gonorrhoea  • Lower respiratory tract infections • Acute bacterial otitis media • Skin and skin structure infections • Acute bacterial otitis media • Skin and skin structure infections • Skin and skin structure infections • Wrinary tract infections • Unirary tract infections • Unirary tract infections • Intra-abdominal infections • Intra-abdominal infections • Meningitis • Surgical prophylaxis • Constipation • Hepatic encephalopathy • Constipation • Hepatic encephalopathy • Constipation • Acinetobacter induced: • Nosocomial Pneumonia • Bacteremia • UTI • Surgical Site wound infections • Post neurological meningitis • Lower Respiratory Tract Infections				
SUPRAVA 12™  Cettriaxone 1 g + 1azobactam 125mg  Skin and skin structure infections  Uncomplicated gonorrhoea  Lower respiratory tract infections  Acute bacterial otitis media Skin and skin structure infections  Acute bacterial otitis media Skin and skin structure infections  Acute bacterial otitis media Skin and skin structure infections  Intra-abdominal infections  Meningitis Surgical prophylaxis  Surgical prophylaxis  Centralose®  Lactulose 100ml / 200ml / 500ml  BULKOSE™  Lactulose + Ispaghula husk 120g  Acinetobacter induced: Nosocomial Pneumonia Butch acinetobacter induced: Nosocomial Pneumonia Bacteremia UTI Surgical Site wound infections Post neurological meningitis  Lower Respiratory Tract infections  Lower Respiratory Tract infections				community-acquired pneumonia
SUPRAVA™  Ceftriaxone 500mg / 1g  Ceftriaxone 500mg /	12	SUPRAVA TZ™	Ceftriavone 1 g + Tazohactam 125mg	Acute bacterial otitis media
Uncomplicated gonorrhoea    Lower respiratory tract infections	13		Certifiaxone 1 g + razobactam 125mg	Skin and skin structure infections
Ceftriaxone 500mg / 1g      Constipation				Urinary tract infections
SUPRAVA™     Ceftriaxone 500mg / 1g     Ce				Uncomplicated gonorrhoea
SUPRAVA™  Ceftriaxone 500mg / 1g  Ceftriaxone 500mg / 1g  Urinary tract infections Bone and joint infections Intra-abdominal infections Meningitis Surgical prophylaxis  Constipation Hepatic encephalopathy  Lactulose 100ml / 200ml / 500ml  BULKOSE™ Lactulose + Ispaghula husk 120g  Constipation Acinetobacter induced: Nosocomial Pneumonia Bacteremia UTI Surgical Site wound infections Post neurological meningitis Lower Respiratory Tract Infections				Lower respiratory tract infections
SUPRAVA™ Ceftriaxone 500mg / 1g  • Urinary tract infections • Bone and joint infections • Intra-abdominal infections • Meningitis • Surgical prophylaxis  • Constipation  BULKOSE™ Lactulose 100ml / 200ml / 500ml  • Constipation  • Constipation  Acinetobacter induced: • Nosocomial Pneumonia • Bacteremia • UTI • Surgical Site wound infections • Post neurological meningitis • Lower Respiratory Tract Infections				Acute bacterial otitis media
Bone and joint infections intra-abdominal infec				Skin and skin structure infections
Bone and joint infections Intra-abdominal infections Intra-abdominal infections Meningitis Surgical prophylaxis  Surgical prophylaxis  Constipation  Hepatic encephalopathy  Lactulose + Ispaghula husk 120g  Constipation  Acinetobacter induced: Nosocomial Pneumonia Bacteremia UTI Surgical Site wound infections Post neurological meningitis Lower Respiratory Tract Infections		CLIDDALIATH	C-4-i	Urinary tract infections
Meningitis     Surgical prophylaxis     Surgical prophylaxis     Surgical prophylaxis     Constipation     Hepatic encephalopathy     Lactulose + Ispaghula husk 120g     Constipation  Acinetobacter induced:     Nosocomial Pneumonia     Bacteremia     UTI     Surgical Site wound infections     Post neurological meningitis     Lower Respiratory Tract Infections	14	SUPRAVA	Certriaxone Soonig / 1g	Bone and joint infections
Meningitis     Surgical prophylaxis     Surgical prophylaxis     Surgical prophylaxis     Constipation     Hepatic encephalopathy     Lactulose + Ispaghula husk 120g     Constipation  Acinetobacter induced:     Nosocomial Pneumonia     Bacteremia     UTI     Surgical Site wound infections     Post neurological meningitis     Lower Respiratory Tract Infections			Lactulace 100ml / 200ml / 500ml	Intra-abdominal infections
15 GENTALOSE® Lactulose 100ml / 200ml / 500ml  16 BULKOSE™ Lactulose + Ispaghula husk 120g  17 Acinetobacter induced:  18 Noscomial Pneumonia  19 Bacteremia  10 UTI  11 Surgical Site wound infections  12 Post neurological meningitis  13 Output Description  15 Constipation  16 Acinetobacter induced:  17 Noscomial Pneumonia  18 Bacteremia  18 UTI  19 Surgical Site wound infections  19 Post neurological meningitis  10 Ower Respiratory Tract Infections		CENTAL OCE®		
15 GENTALOSE® Lactulose 100ml / 200ml / 500ml  16 BULKOSE™ Lactulose + Ispaghula husk 120g  17 Acinetobacter induced:  18 Noscomial Pneumonia  19 Bacteremia  10 UTI  11 Surgical Site wound infections  12 Post neurological meningitis  13 Output Description  15 Constipation  16 Acinetobacter induced:  17 Noscomial Pneumonia  18 Bacteremia  18 UTI  19 Surgical Site wound infections  19 Post neurological meningitis  10 Ower Respiratory Tract Infections				Surgical prophylaxis
Hepatic encephalopathy      Constipation      Acinetobacter induced:     Nosocomial Pneumonia     Bacteremia     UTI     Surgical Site wound infections     Post neurological meningitis     Our Respiratory Tract Infections     Nose Respiratory Tract Infections	15			
Acinetobacter induced:  • Nosocomial Pneumonia  • Bacteremia  • UTI  • Surgical Site wound infections  • Post neurological meningitis  • Lower Respiratory Tract Infections	15	GENTALOSE	Lactulose 100mi / 200mi / 500mi	Hepatic encephalopathy
Nosocomial Pneumonia      MATABAC™  Sulbactam 1g / 2g      **Bacteremia**     **UTI**  Surgical Site wound infections  Post neurological meningitis  Output  Lower Respiratory Tract Infections	16	BULKOSE™	Lactulose + Ispaghula husk 120g	Constipation
MATABAC™  Sulbactam 1g / 2g  • Bacteremia • UTI • Surgical Site wound infections • Post neurological meningitis • Lower Respiratory Tract Infections				Acinetobacter induced:
MATABAC Sulbactam 1g / 2g  - UTI - Surgical Site wound infections - Post neurological meningitis - Lower Respiratory Tract Infections				Nosocomial Pneumonia
UTI     Surgical Site wound infections     Post neurological meningitis     Lower Respiratory Tract Infections		MATADACIM	Sulhactam 1a / 2a	Bacteremia
Post neurological meningitis     Lower Respiratory Tract Infections		MATABAC'™	SAC Sulpactam 1g / 2g	• UTI
Lower Respiratory Tract Infections				Surgical Site wound infections
				Post neurological meningitis
a Skin and Skin Structura Infactions		MEEZAT™	Ceftazidime 1g	Lower Respiratory Tract Infections
• Skin and Skin-Structure injections				Skin and Skin-Structure Infections
Urinary Tract Infections				Urinary Tract Infections
Bacterial Septicemia				Bacterial Septicemia
MEEZA1*** Certazidime 1g  • Bone and Joint Infections				
Gynecologic Infections				
Intra-abdominal Infections				
Central Nervous System Infections				
Dialysis and continuous venomous hemofiltration	47	TI HAH ATM	U	
17 THINLA™ Heparin 5000 IU / 25000IU  - Obrigos and continuous reinformation  - As prophylaxis in ACS, PCI, DVT  - As prophylaxis in ACS, PCI, DVT	1/	I MINLA	neparin 5000 to / 2500010	

Sl. No.	Bioproducts		
			Cirrhosis and Liver cirrhosis
1	ALBUBET Safe	Human Albumin Solution Ph. Eur (20%)	Hypovolemic shock
			Major Burns
	IVNEX™ Safe	Human Normal Immunoglobulin for Intravenous Administration Ph. Eur. 5g	Primary Immunodeficiency Diseases
2			Guillain Barre Syndrome
			Idiopathic Thrombocytopenic Purpura
			Kawasaki Disease
			Bleeding oesophageal Varices
3	ZOMATOR™	Somatostatin 250 mcg and 3 mg	Non variceal upper GI bleeding
			Treatment of postoperative complications and prophylaxis following pancreatic surgery
			Treatment of intestinal, biliary and pancreatic fistulae